国际新闻精选周三（2017年1月11日）

JP Morgan day one roundup – deals and guidance abound

Day one of the JP Morgan conference delivered what many must have been hoping for: three deal announcements no doubt timed to grab the attention of the assembled masses. Still, there will be hopes for more news on the corporate transaction front in the coming days as the sector seeks to rediscover its mojo. 【阅读全文】

Moderna finally unveils pipeline at JPM, with 5 candidates in testing

Moderna, often accused of being secretive after failing to reveal, publicly at least, its pipeline of meds, finally did so on Monday with its candidates targeting a host of infectious diseases, I-O and CV diseases. In one of the more anticipated sessions of this week’s J.P. Morgan Healthcare Conference in San Francisco, the private company, believed to be worth up to $5 billion, says it has 12 mRNA development candidates that include vaccines and therapeutics across the three therapeutic areas.【阅读全文】

Valeant Sells $2.1 Billion in Assets to Ease Debt Burden

Valeant Pharmaceuticals International Inc. agreed to sell about $2.1 billion in assets in two deals, an important first step in the struggling drugmaker’s endeavor to get cash and begin easing its debt burden. L’Oreal SA, the Paris-based cosmetic giant, will pay Valeant $1.3 billion for three skin-care brands, according to a statement Tuesday. Valeant will also sell its Dendreon Pharmaceuticals unit to closely held Chinese conglomerate Sanpower Group Co. for about $820 million. Valeant’s shares and bonds jumped after the news.【阅读全文】

Kite, Fosun Pharma form JV in China for cancer treatment

Kite Pharma Inc said on Tuesday it had formed a joint venture with Shanghai Fosun Pharmaceutical (Group) Co Ltd to develop and commercialize its cancer treatment in China. Kite Pharma said it would receive an upfront payment of $40 million from the JV, funded by Fosun Pharma as well as regulatory and commercial milestones totaling $35 million. 【阅读全文】

Dublin, Ireland-based Allergan has stepped into the field of Parkinson's disease with an option to acquire US-based neurodegenerative research group Lysosomal Therapeutics (LTI).

LTI-291, LTI's lead programme, is designed to stimulate the activity of glucocerebrosidase (GCase) in the brain, which is reduced in many lysosomal storage diseases because of mutations in the GBA1 gene.【阅读全文】

Amgen, Immatics link in $1.3bn cancer deal

US biotech giant Amgen and Germany's Immatics Biotechnologies GmbH have announced a deal potentially worth more than $1.3 billion to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers.The firms are planning to utilise Immatics' XPRESIDENT target discovery and T-cell receptor (TCR) capabilities and Amgen's validated Bispecific T-cell Engager (BiTE) technology to create novel oncology drugs.【阅读全文】

Illumina Promises To Sequence Human Genome For $100 -- But Not Quite Yet

Illumina, the largest maker of DNA sequencers, is launching a new DNA sequencer with new architecture it says could push the cost of decoding a human genome from $1,000 to $100–although that decrease will not come for years. “This is good news, affirming that the field is still so healthy that price-plummeting is still considered good for business,” says George Church, the Robert Winthrop Professor of Genetics at Harvard Medical School.【阅读全文】

★ 请关注《美中药源》微信公众号 ★